Issue of Shares

LONDON and SALT LAKE CITY - 10 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), announces the repayment of $1.06 million of principal and interest amount due under the Company's convertible bonds for the period from 8 January 2024 to 7 April 2024, further details of the convertible bonds were announced on 31 March 2022. The repayment of the principal and interest amount due for the period is being made through the issue of 1,818,081 American Depositary Shares ("ADSs") representing 3,636,162 ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") on 11 April 2024.

After settlement of the repayment, the principal remaining under the convertible bonds will be reduced by $1.06 million to $12.72 million.

An application has been made to the London Stock Exchange plc for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 3,636,162 new Ordinary Shares to trading on AIM will become effective on, or around, 8 a.m. UK time on 12 April 2024. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.

Total voting rights

Following the allotment and issue of the 3,636,162 new Ordinary Shares, the Company will have 123,552,349 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company will therefore be 123,552,349.

The International Securities Identification Number for the Ordinary Shares is GB00BYWL4Y04.